RPRX in the 13F filings
Royalty Pharma PLC · CUSIP G7709Q104
- Quarter end
- 31 Dec 2023
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 26 Jan 2024
- Managers listing it
- 13
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q3 2023 and Q4 2023; 11 listed it in both
- Shares listed
- 73,423,962
- combined, among listed positions
- Reported value
- $2.1bn
- combined, at the quarter end
Among the 93 comparable managers: 8 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing RPRX in Q4 2023
13 of 13 holders
Largest increases and reductions, by shares
Increases
- Man Group PLCexisting position · 2,579,152 shares now+1,445,537
- Fidelity (FMR LLC)existing position · 31,583,929 shares now+1,156,757
- Viking Global Investors LPexisting position · 10,087,417 shares now+623,216
- Point72 Asset Management LPexisting position · 1,168,800 shares now+440,600
- Hudson Bay Capital Management LPnew position · 160,000 shares now+160,000
Reductions
- Baillie Gifford & Coexisting position · 17,590,450 shares now-650,834
- Janus Henderson Group Ltdexisting position · 1,900,614 shares now-335,782
- Arrowstreet Capital LPexisting position · 1,779,236 shares now-174,006
- Two Sigma Investments LPexisting position · 2,111,268 shares now-95,447
- Squarepoint Ops LLCexisting position · 900,894 shares now-55,662
New positions and exits
New (1)
Exited (1)
- Rokos Capital Management LLPwas $30m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2020 | 10 | $1.8bn | n.a. | n.a. |
| Q3 2020 | 7 | $1.6bn | n.a. | n.a. |
| Q4 2020 | 5 | $1.9bn | n.a. | n.a. |
| Q1 2021 | 5 | $1.5bn | n.a. | n.a. |
| Q2 2021 | 8 | $1.5bn | n.a. | n.a. |
| Q3 2021 | 6 | $1.4bn | n.a. | n.a. |
| Q4 2021 | 8 | $1.8bn | n.a. | n.a. |
| Q1 2022 | 8 | $1.8bn | n.a. | n.a. |
| Q2 2022 | 10 | $3.2bn | n.a. | n.a. |
| Q3 2022 | 11 | $3.4bn | n.a. | n.a. |
| Q4 2022 | 17 | $3.4bn | n.a. | n.a. |
| Q1 2023 | 14 | $2.9bn | n.a. | n.a. |
| Q2 2023 | 16 | $2.3bn | n.a. | n.a. |
| Q3 2023 | 14 | $1.9bn | n.a. | n.a. |
| Q4 2023 | 13 | $2.1bn | 8 | 6 |
| Q1 2024 | 10 | $2.2bn | 5 | 6 |
| Q2 2024 | 12 | $1.7bn | 7 | 5 |
| Q3 2024 | 10 | $2.0bn | 7 | 4 |
| Q4 2024 | 10 | $1.6bn | 7 | 3 |
| Q1 2025 | 9 | $2.3bn | 4 | 5 |
| Q2 2025 | 9 | $2.4bn | 4 | 5 |
| Q3 2025 | 11 | $1.9bn | 7 | 5 |
| Q4 2025 | 10 | $2.4bn | 17 | 14 |
| Q1 2026 | 15 | $3.1bn | 18 | 16 |
| Q2 2026 | 15 | $3.9bn | 21 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
RPRX and LLY →RPRX and JNJ →RPRX and VRTX →Choose a stock to compare with RPRX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own RPRX, latest filings →Back to the 13F Explorer →